Few Eyebrows Up

Nov 02, 2018

Some experts have raised concerned about 23andMe's new direct-to-consumer pharmacogenetic tests, Time reports.

The US Food and Drug Administration earlier this week gave 23andMe authorization to sell tests for 33 variants linked to the ability to break down certain drugs, as GenomeWeb has reported.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

P.1 Re-infection Concerns

New analyses indicate the P.1 variant found in Brazil may be able to infect people who have already had COVID-19, the New York Times reports.

Aiming for May

According to CNBC, Novavax's CEO says its vaccine could be authorized in the US as early as May.

NIH Program to Address Structural Racism

The US National Institutes of Health has a new initiative to address structural racism in biomedical research.

PNAS Papers on Myelopathy GWAS in Japan, Hypertrophic Cardiomyopathy, MRSA Methylation

In PNAS this week: GWAS of TLV-1-associated myelopathy/tropical spastic paraparesis, analysis of twins with hypertrophic cardiomyopathy, and more.

Menu

Few Eyebrows Up

To read the full story....

The Scan

P.1 Re-infection Concerns

Aiming for May

NIH Program to Address Structural Racism

PNAS Papers on Myelopathy GWAS in Japan, Hypertrophic Cardiomyopathy, MRSA Methylation

What's Popular?

Agilent Technologies to Acquire Liquid Biopsy Firm Resolution Bioscience for up to $695M

Twist Bioscience, Watchmaker Genomics Partner on High-Throughput NGS Applications

Myriad Genetics, Intermountain Healthcare Collaborate for Cancer Testing Service

Quidel Stock Plunges in February as GenomeWeb Index Falls 3 Percent

Guardant360 CDx Receives CE Mark for Tumor Mutational Profiling and Tagrisso CDx Use

Sponsorships